The onset and progress of Type I (insulin-dependent) diabetes mellitus is variable. Some patients develop disease early in life with a very short duration of symptoms, and others become insulin-dependent after years of abnormal glucose tolerance or after years of what has been called Type2 (non-insulin-dependent) diabetes mellitus. In a few patients infections or toxic agents have provoked or triggered the disease; in others the disease appears some time after certain infections [1, 2] . In most patients, however, no single exogenous factor can be identified as the cause. Autoimmune phenomena seem to be involved in the development of Type 1 diabetes [3] . Some studies have indicated that HLA-DR 3, in particular, is connected to autoimmune reactions [4, 5] . In an earlier study [6] we found differences regarding early manifestations of Type 1 diabetes between patients with HLA-DR3 or HLA-DR4 which supported the hypothesis that Type i diabetes may have a heterogeneous background. Patients with HLA-DR 3 had a tendency towards a milder onset of Type 1 diabetes than those with HLA-DR4. The aim of this study was to confirm, on a larger patient group, that there is an association between disease progress and certain HLA antigens and to analyse whether this could in part explain differences associated with sex, age or season of diagnosis of Type 1 diabetes.
Subjects and methods
A questionnaire was mailed to those members of the International Study Group of Diabetes in Children and Adolescents (ISGD) who agreed to participate in the study (Table 1) . Answers were returned regarding 745 HLA-DR-typed diabetic children, 389 (52%) boys and 356 (48%) girls, from the different countries (Table 2) .
Their age at onset varied between 1-19 years, with a distribution as shown in Figure1. Thus, in the age group 0-4years, boys were overrepresented (p < 0.02). This distribution was very similar in the different participating centres.
Statistical analysis
The Z2-test was used for statistical evaluation. In the case of several comparisons, the p value was corrected by multiplying p by the number of comparisons. 
Results
The distribution of HLA-DR-types is shown in Table 3 . HLA-DR3 and/or HLA-DR4 was found in 678/745 (91%) of the patients and DR 2 in only 47 patients (6%), of whom 16 had HLA-DR3 and 16 HLA-DR4. Of the 646 patients with HLA-DR3 and/or 4 but without HLA-DR2, girls were somewhat overrepresented among HLA-DR4/non 3 (125/235, 53%) compared to DR3/non 4 (72/167, 43%) (p<0.05). This sex difference was especially pronounced in the USA, although the same tendency was apparent among the European patients (Table 4) . Table 4 reveals some differences between the countries. In Sweden there were relatively few patients with DR 2, or patients lacking both DR 3 and 4 compared to the other countries, but many patients with DR4. In France there was a higher frequency of HLA-DR 3 and more cases lacking both DR3 and 4. Age at diagnosis in relation to some HLA-DR-types is shown in Figure2. Patients with DR4 and DR3/4 tended to develop manifest diabetes earlier with incidence peaks both around 7-8 years and 10-11 years, while the DR 3 patients lacked these incidence maxima and had rather stable incidence from 4years up to 12years, when incidence increased to a peak around 14 years. However, the difference is not significant for individual years. The seasonal variation is shown in Figure 3 . Patients with DR 4 had wider seasonal variation than DR 3 patients, as DR 3 patients had no incidence peak during summer. Duration of symptoms before diagnosis was usually 1-3 weeks, but varied from a few days to a year. A duration of less than 7 days was noticed in 132patients, of whom only 4 were HLA-DR3/3 or-(p <0.02).
At diagnosis 15% of the patients were said to have impaired consciousness (including 4% in coma). In this regard DR 3 patients again differed, showing impaired consciousness significantly less often than DR4 or 209 DR4/4 patients (/7<0.05). This difference was even more marked when we compared ketonuria (Fig.4 , p < 0.01). High blood glucose at onset (> 20 mmol/ml) tended to be found somewhat more often among patients with HLA-DR 3/4 or DR 4 than among those with DR 3 (p < 0A). No information could be obtained from Pittsburgh regarding partial remission, but in the other centres partial remission was observed according to Figure 5 , which reveals only a tendency (p <0.1) for DR 3 patients to more often have remission > 6 months than the others. When comparing DR3/3 or DR3/0 with DR4/4 or DR4/0, as well as comparing DR3/3 or DR 3/0 with DR 3/4, this tendency becomes stronger (p < 0.01, p < 0.01 respectively).
The differences between HLA-DR3-patients and those with HLA-DR3/4 or 4 described above were found with varying significance, but always with the same tendencies within each country. We also obtained the same result if the four clinics wkh low numbers of patients were excluded. Except for the mentioned differences in age at diagnosis and frequency of HLA-DR4, there was no significant sex difference.
Discussion
There are several methodological problems with this multicentre study, as different centres may have used slightly different definitions of the various clinical parameters and different laboratory methods. Such errors should blunt the results and make it even more difficult to find significant differences between the groups. It is, therefore, the more remarkable that we can confirm that there are indeed differences in the clinical presentation and course between patients with HLA-DR 3 and those with HLA-DR4 or 3/4 in this large, heterogeneous group [6, 7] . The DR 3 patients more often have a slower onset, spread more evenly over the year, less often have severe symptoms and ketonuria, but more often have partial remission. These differences were seen within each sex. The same tendencies are seen in different parts of Europe and in the USA, even if there are some HLA differences such as the more homogeneous DR 3 and/or 4diabetic population in Sweden than in the other studied countries. The sex differences, with more boys with onset at less than 5 years of age and more girls with DR 4 alone, do not explain the differences seen between the HLA-DR types. Above the age of 4 the HLA-DR types seem to be related to the incidence, as HLA-DR 4 patients have an extra peak in the summer as well as the peak in early spring which is seen in all groups. Furthermore, the second peak occurs later for DR3/4 patients (autumn) and is lacking for DR 3 patients [7] . One could speculate on the possibility that DR4 patients have a tendency to certain infections [4] , which explains their extra peak, while DR 3 individuals tend to modulate the seasonal variation by its slower progress. The observation that all groups, including DR 3, have a peak in early spring, could reflect the influence of several factors like infections, inactivity, seasonal hormonal variation, etc. -factors which may influence rather than cause the manifest disease. HLA-DR 2 is rarely seen as expected [8, 9] , but nonetheless there are some patients with DR2 and with neither DR3 nor DR4 who get Type 1 diabetes. These patients do not differ in the variables we have analysed; they are, however, an interesting group which should be studied in more detail to determine if environmental factors could be involved in the etiology of their diabetes or if their DR2 includes subtypes.
In conclusion, this study confirms that there are significant differences between those diabetic children who have HLA-DR3 in comparison with those who have DR4 or both DR3/4. Thus, the phenotype expression of disease is modified by the genotype. Patients who possess an HLA-DR 3 antigen generally have a milder form of disease than patients without this marker.
